Seven of nine treated eyes maintained foveal schisis closure at 12 months — a structural outcome not seen in a single untreated control eye — and that asymmetry is doing a lot of work for Atsena Therapeutics as it prepares to move ATSN-201 into a pivotal Phase 3. The LIGHTHOUSE Trial’s Part A data, presented at ARVO 2026, also showed statistically significant improvements across microperimetry, best-corrected visual acuity, and low-luminance visual acuity, with zero drug-related serious adverse events and zero discontinuations across all nine adult patients. For a disease — X-linked retinoschisis — that has no approved treatments and roughly 30,000 affected males in the U.S. and EU, this is the cleanest early-stage safety-efficacy profile the field has seen from any XLRS program.
The ATSN-101 picture for LCA1 is older and arguably more consequential. Fifteen patients at three years post-treatment, with high-dose recipients sustaining a mean 20-decibel improvement in dark-adapted full-field stimulus testing — a 100-fold gain in light sensitivity that has not eroded. Durability at 36 months is the hardest thing to demonstrate in retinal gene therapy, and the absence of attenuation here directly counters the skepticism that shadowed earlier AAV programs where functional gains peaked and then retreated. Atsena expects to initiate a global pivotal Phase 3 for ATSN-101 in the second half of 2026, which means both programs will be in late-stage development simultaneously — an unusual position for a company that has yet to file a BLA.
The methodological decision embedded in the LCA1 program deserves scrutiny. Atsena is replacing the standard Multi-Luminance Mobility Test with a modified version — the modMLMT — specifically engineered to capture functional gains in patients with retained rod function. The standard MLMT, designed around cone-dependent navigation, structurally underestimates treatment effect in a rod-dominant disease like LCA1. The modMLMT detected a treatment signal in more ATSN-101 patients than the conventional test. Using a novel endpoint in a pivotal trial is a regulatory wager: FDA will need to accept the modMLMT as adequate evidence of clinical benefit, and the agency’s comfort with that instrument becomes the single most important variable between now and a BLA submission.
Watch the FDA’s formal endpoint alignment for the LCA1 pivotal trial. If the modMLMT clears as a primary endpoint without a post-hoc rescue requirement, Atsena’s regulatory path compresses substantially; if it doesn’t, the company faces a redesign that pushes the ATSN-101 BLA well past the 2028 horizon it has set for ATSN-201.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
